Back to News
Market Impact: 0.2
Tempus AI's Ambry Genetics Launches GenomeNext To Improve Rare Disease Diagnosis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Tempus AI said its wholly owned subsidiary, Ambry Genetics, launched GenomeNext and GenomeReveal, a whole genome sequencing solution intended to improve diagnosis for patients with rare diseases. The announcement included no pricing, expected uptake, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TEM0.65
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- Mainspring, AEP Strike Deal to Bring Power Online Faster
- Why this little known Chinese chipmaker has caused a global stock rout
- Applied Materials CEO on Doubling Revenue Thanks To AI